Epidemiology of Heart Failure

Chapter

Abstract

Heart failure affects approximately 2 % of the adult population. Incidence and prevalence are strongly age related with effectively a doubling of prevalence for each decade of age, with prevalence rates of 1 % for people age 50–59 years and increasing to 10 % for those age 80–89 years. The lifetime risk of developing heart failure is between one in four and one in three people over the age of 40–55 years. Morbidity and mortality remain high for patients with heart failure, and healthcare costs consume up to 2 % of total health budgets in most developed countries. This chapter will review the current literature on the epidemiology of heart failure.

Keywords

Heart failure Incidence Prevalence Mortality Hospitalization Healthcare costs 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    The Taskforce on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J. 1995;16:741–51.Google Scholar
  2. 2.
    Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. BMJ. 1994;308:321–8.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Dougherty AH, Naccarelli GV, Gray EL. Congestive heart failure with normal systolic function. Am J Cardiol. 1984;54:778–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Ramachandran SV, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–74.CrossRefGoogle Scholar
  5. 5.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol. 2001;38:2101–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health. 1951;41:279–86.CrossRefGoogle Scholar
  7. 7.
    McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of heart failure: the Framingham study. N Engl J Med. 1971;285:1141–6.CrossRefGoogle Scholar
  8. 8.
    Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281–90.PubMedGoogle Scholar
  9. 9.
    Ho KKL, Anderson KM, Kannel WB. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation. 1993;88:107–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Remes J, Reuanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 1992;13:588–93.PubMedGoogle Scholar
  11. 11.
    Murphy NF, Simpson CR, McAlister FA, et al. National survey of the prevalence, incidence, primary care burden and treatment of heart failure in Scotland. Heart. 2004;90:1129–36.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Devroey D, Van Casteren V. The incidence and first-year mortality of heart failure in Belgium: a 2-year nationwide prospective registration. Int J Clin Pract. 2010;64:330–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Senni M, Tribouilloy CM, Redeheffer RJ, et al. Congestive heart failure in the community. Trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.CrossRefPubMedGoogle Scholar
  15. 15.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update. Circulation. 2011;123:e18–209.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Smith WM. Epidemiology of congestive heart failure. Am J Cardiol. 1985;55:3A–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Bleumink GS, Knetsch AM, Sturkenboom MCJM, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study. Eur Heart J. 2004;25:1614–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Eriksson H, Svardsudd K, Caidahl K, et al. Early heart failure in the population. The study of men born in 1913. Acta Med Scand. 1988;223:197–209.CrossRefPubMedGoogle Scholar
  19. 19.
    Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Heart Study. J Am Coll Cardiol. 1993;22:6A–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Butler RN. Population aging and health. Br Med J. 1997;315:1082–4.CrossRefGoogle Scholar
  21. 21.
    US Census Bureau. USA quick facts. 2011 doi: http://quickfacts.census.gov/qfd/states/00000.html.
  22. 22.
    Statistics New Zealand. Demographic aspects of New Zealand’s ageing population. Wellington: Statistics New Zealand; 2008.Google Scholar
  23. 23.
    Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Ghali JK, Cooper R, Ford E. Trends in hospitalisation rates for heart failure in the United States, 1973–1986. Arch Intern Med. 1990;150:769–73.CrossRefPubMedGoogle Scholar
  25. 25.
    McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland, 1980–1990. Eur Heart J. 1993;14:1158–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 1993;126:1042–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Reitsma JB, Mosterd A, de Craen AJM, et al. Increase in hospital admission rates for heart failure in the Netherlands, 1980–1993. Heart. 1996;76:388–92.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Doughty R, Yee T, Sharpe N, MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988–91. N Z Med J. 1995;108:473–5.PubMedGoogle Scholar
  29. 29.
    Rodriguez-Artalejo F, Guallar-castillon P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalisation and mortality for heart failure in Spain, 1980–1993. Eur Heart J. 1997;18:1771–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalisation for heart failure. J Am Geriatr Soc. 1997;45:270–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Roughead LE, Gilbert AL. Australian trends in hospitalisation and mortality associated with chronic heart failure. Med J Aust. 1998;168:256.PubMedGoogle Scholar
  32. 32.
    Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalisation of patients with heart failure: National Hospital Discharge Survey, 1985–1995. Am Heart J. 1999;137:352–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Ni H, Nauman DJ, Hershberger RE. Analysis of trends in hospitalisations for heart failure. J Card Fail. 1999;5:79–84.CrossRefPubMedGoogle Scholar
  34. 34.
    Mosterd A, Hoes AW. Epidemiology of heart failure: what does the future hold? In: McMurray JJV, Cleland JG, editors. Heart failure in clinical practice. 2nd ed. London: Martin Dunitz; 2000. p. 3–17.Google Scholar
  35. 35.
    Wasywich CA, Gamble GD, Whalley GA, Doughty RN. Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of “days alive and out of hospital” from epidemiological data. Eur J Heart Fail. 2010;12:462–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara PM. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99–104.CrossRefPubMedGoogle Scholar
  39. 39.
    American, Heart, Association. Heart and stroke statistical update. Dallas: American Heart Association; 2002.Google Scholar
  40. 40.
    McMurray M, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P):P9–16.PubMedGoogle Scholar
  41. 41.
    McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ. 1993;6:99–110.Google Scholar
  42. 42.
    Tavazzi L. Epidemiological burden of heart failure. Heart. 1998;79 (Suppl 2):S6–9.Google Scholar
  43. 43.
    Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–22.CrossRefPubMedGoogle Scholar
  44. 44.
    MacIntyre K, Capewell S, Stewart S, Chalmers JWT. Evidence of improving prognosis in heart failure: trends in case fatality in 66547 patients hospitalised between 1986 and 1995. Circulation. 2000;102:1126–31.CrossRefPubMedGoogle Scholar
  45. 45.
    Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J. 2003;146:258–64.CrossRefPubMedGoogle Scholar
  46. 46.
    Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001. Heart. 2003;89:615–20.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J. 2004;25:300–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Cleland JGF, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The national heart failure audit for England and Wales 2008–2009. Heart. 2010;97:876–86.CrossRefPubMedGoogle Scholar
  49. 49.
    The CONSENSUS trial study group. Effects of enalapril on mortality in severe heart failure: the results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRefGoogle Scholar
  50. 50.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefGoogle Scholar
  51. 51.
    CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRefGoogle Scholar
  52. 52.
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRefGoogle Scholar
  53. 53.
    Pfeffer M, Swedberg K, Granger CB, et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003;362:759–66.Google Scholar
  54. 54.
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.CrossRefPubMedGoogle Scholar
  55. 55.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.CrossRefPubMedGoogle Scholar
  56. 56.
    Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.CrossRefPubMedGoogle Scholar
  57. 57.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.CrossRefPubMedGoogle Scholar
  60. 60.
    Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77.CrossRefPubMedGoogle Scholar
  61. 61.
    Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–27.CrossRefPubMedGoogle Scholar
  62. 62.
    Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.CrossRefPubMedGoogle Scholar
  63. 63.
    Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.CrossRefPubMedGoogle Scholar
  64. 64.
    Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.CrossRefPubMedGoogle Scholar
  65. 65.
    MAGGIC Collaborative Group. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33:1750–7.CrossRefGoogle Scholar
  66. 66.
    Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Bourassa MG, Gurne O, Bangdiwala SI, for the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Natural history and patterns of current clinical practice in heart failure. J Am Coll Cardiol. 1993;22(Suppl A):14A–19A.Google Scholar
  68. 68.
    Levy D, Larson D, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. J Am Med Assoc. 1996;275:1557–62.CrossRefGoogle Scholar
  69. 69.
    Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the heart of Soweto Study cohort. Circulation. 2008;118:2360–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Albert MA. Heart failure in the urban African enclave of Soweto. Circulation. 2008;118:2323–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Killip T, Kimball J. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol. 1967;20:457–64.CrossRefPubMedGoogle Scholar
  72. 72.
    Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389–94.CrossRefPubMedGoogle Scholar
  73. 73.
    Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J. 2004;25:1911–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Stewart S, MacIntyre K, Capewell S, McMurray JJV. Heart failure and the aging population: an increasing burden in the 21st century? Heart. 2003;89:49–53.PubMedCentralCrossRefPubMedGoogle Scholar
  76. 76.
    Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest. 1999;115:867–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Shindler DM, Kostis JB, Yusuf S, et al. for the SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017–20.Google Scholar
  78. 78.
    Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Eur Heart J. 1999;20:789–95.CrossRefPubMedGoogle Scholar
  79. 79.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–31.CrossRefPubMedGoogle Scholar
  80. 80.
    Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson A-M, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378:140–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.CrossRefPubMedGoogle Scholar
  82. 82.
    Loehr LR, Rosamond WD, Poole C, et al. The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. Am J Epidemiol. 2010;172:781–9.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Department of CardiologyThe University of Auckland and Greenlane Cardiovascular Service, Auckland District Health BoardAucklandNew Zealand
  2. 2.Green Lane Cardiovascular Services, Cardiology DepartmentAuckland City HospitalAucklandNew Zealand

Personalised recommendations